Positive efficacy and tolerance in pediatric trial

AI SummaryClose X

Shield Therapeutics announced the presentation of positive results from its Phase 3 pediatric trial (FORTIS) for ACCRUFeR® at the American Association of Pediatrics (AAP) National Conference. The trial demonstrated clinically and statistically significant hemoglobin improvements versus baseline across all groups, including ferric maltol and ferrous sulfate arms, with a P value of less than 0.0001. Notably, no patients discontinued ferric maltol treatment due to adverse events, while one patient discontinued from the ferrous sulfate arm. Treatment-related adverse events were reported in 6.5% of patients treated with ferric maltol compared to 13% of patients treated with ferrous sulphate, and no treatment-related serious adverse events were reported in either group.

Disclaimer*

UK 100

Latest directors dealings